Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting

Purpose: We compared the efficacy of intravitreal ranibizumab and bevacizumab for treating neovascular age-related macular degeneration using an on-demand regimen.

Methods: A total of 186 wet age-related macular degeneration eyes of 186 treatment-naïve patients were compared retrospectively (67 eyes treated with ranibizumab with 91 treated with bevacizumab). At baseline, mean age, best corrected visual acuity, and angiographic lesion types were similar in both groups. Best corrected visual acuity and ocular coherence tomography were evaluated.

Results: Sixty eyes treated with ranibizumab and 85 eyes treated with bevacizumab completed a 12-month evaluation. At 12 months, mean best corrected visual acuity increased by +6.65 letters with ranibizumab treatment and by +5.59 with bevacizumab treatment (P = 0.64). Visual acuity improved by ≥15 letters in 15 eyes treated with ranibizumab and in 21 eyes treated with bevacizumab (P = 0.75). An overall reduction in ocular coherence tomography central thickness occurred for all time points. The mean number of injections per eye was 5.97 with ranibizumab and 5.92 with bevacizumab (P = 0.90).

Conclusion: Intravitreal therapies with ranibizumab or bevacizumab have similar visual and anatomical results. These results confirm those of comparison of Age-Related Macular Degeneration Treatment Trials in as-needed cohorts in clinical practice. Randomized long-term clinical trials are necessary to examine the systemic safety of these treatments.

Keywords: AMD, anti-VEGF therapy, bevacizumab, choroidal neovascularization, ranibizumab, wet AMD

Introduction

Choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) is the leading cause of severe central vision loss in individuals over the age of 65 years in Europe, North America, and Australia. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab (Lucentis®, Novartis Pharma AG, Basel, Switzerland and Genentech, South San Francisco, California) and bevacizumab (Avastin®, Genentech, South San Francisco, California) has revolutionized the management of this disease, as these were the first forms of treatment that significantly improved visual acuity in patients with neovascular AMD.

Bevacizumab is a full-length, recombinant, humanized, monoclonal antibody with a molecular weight of 148 kD, while ranibizumab is a recombinant, humanized, monoclonal Fab fragment of 49 kD. In primate and rabbit studies, a humanized antibody with a framework similar to that of bevacizumab was compared with the Fab version of bevacizumab. Under the tested conditions, Fab showed greater diffusion...
than the IgG; IgG progression stopped either at the outer plexiform or at the internal limiting membrane and did not reach the subretinal space at the same concentration as the Fab fragment.14,15 Thus, ranibizumab was developed as a more effective treatment for CNV. A large number of multicenter controlled clinical trials reported unprecedented visual results for treating wet AMD with ranibizumab.10,12,16–18 Subsequently, ranibizumab was approved by the US Food and Drug Administration and the European Medicines Agency for the treatment of neovascular AMD.

The best visual results were obtained with fixed monthly injections such as in the Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in AMD (ANCHOR) and Minimally Classic/Occult Trial of the Anti-VEGF Antibody Ranibizumab in the Treatment of Neovascular AMD (MARINA) trials.10,12,16,17,19 Attempts to space treatment periods such as in the PIER20 and SAILOR21 trials, with three initial monthly injections followed by a quarterly regimen, resulted in worse visual results at 52 weeks. In the MARINA, ANCHOR, and PIER trials, the greatest visual improvement occurred with the first three injections. This led to Novartis recommending that patients should be treated with an initial 3-injection-loading dose of Lucentis9,22 In clinical practice, after the loading dose, many ophthalmologists use injections “as-needed” or using a pro re nata (PRN) treatment strategy based on clinical and ocular coherence tomography (OCT) data.23–25

Bevacizumab is a VEGF inhibitor that neutralizes all known biologically active isoforms of VEGF-A. The Food and Drug Administration approved its use in 2004 for the intravenous treatment of metastasized colon adenocarcinoma.26,27 After the first intravitreal use of bevacizumab reported in 2005,9 its off-label use for treating wet AMD was widely adopted. The apparent safety and efficacy of intravitreal use of this full-length antibody has been reported following numerous retrospective series and small prospective clinical studies.28,29 Visual improvement can occur immediately after the first injection and many ophthalmologists use bevacizumab in clinical practice using an as-needed or 1+PRN treatment.30,31

The results of several large randomized, double-blind clinical trials comparing the effectiveness of both drugs for treating wet AMD are not yet available (VIBERA NCT00559715, IVAN CT EU Bristol, MANTA NCT00710229, LUCAS NCT01127360, and GEFAL NCT01170767 trials). The recent publication of Age-Related Macular Degeneration Treatment Trials (CATT) results, a prospective, randomized, comparative effectiveness study of bevacizumab and ranibizumab in fixed monthly or as-needed regime of treatment, demonstrated similar efficacy results between the two molecules. However, the bevacizumab as-needed cohort showed inconclusive results when compared to ranibizumab monthly or bevacizumab monthly. Additionally, OCT results were better in ranibizumab-treated patients.13

To date, a limited number of other studies have directly compared the two drugs using the same treatment and retreatment protocols for both drugs.32–35 With some limitations, these studies suggest similar visual outcomes of treatment with the two drugs.

To our knowledge, apart from the CATT, no other published reports have compared both drugs using an 1+PRN strategy of treatment to evaluate efficacy parameters at 1, 2, 3, 4, 5, 6, 9, and 12 months.

In this single-center retrospective analysis we compared the efficacy of bevacizumab and ranibizumab at 12 months using an as-needed or 1+PRN strategy of treatment in a clinical practice setting.

Methods

We conducted a retrospective, observational, uncontrolled, non-randomized and unicentric analysis to compare the efficacy of intravitreal treatments with ranibizumab and bevacizumab for wet AMD. A review of clinical charts of selected patients was performed.

Approval from the Ethics Committee of Hospital São João was obtained for intra-vitreal “off-label” use of bevacizumab in wet AMD in December 2006. Each patient signed a written informed consent. The study was carried out in accordance with the Declaration of Helsinki.

In our department, before ranibizumab availability, patients with wet AMD were treated with intravitreal bevacizumab (1.25 mg). When INFARMED (the Portuguese health authority) approved the use of ranibizumab in Portugal in July 2008, ranibizumab was used (0.5 mg) in our department for treating naïve patients. Therefore, drug choice was not based on medical or social characteristics of the patient, but based solely on enrollment date. Patients enrolled from December 2006 through July 2008 were treated with bevacizumab; patients enrolled after July 2008 were treated with ranibizumab. Therefore, no drug choice was offered to the patient or the ophthalmologist. No patient refused the assigned treatment.

Inclusion and exclusion criteria are summarized in Table 1.

In patients who presented with wet AMD in both eyes, only the right eye was included in the study. Exclusion criteria
Table 1 Inclusion and exclusion criteria

Inclusion criteria
Age-related macular degeneration
Subfoveal CNV
BCVA ≥ 20/1000
Patients must be age 50 years or older
Patients must sign a written informed consent form
In cases of bilateral disease, only the right eye was included

Exclusion criteria
Previous treatment for wet AMD, including laser, radiation, PDT, or any anti-VEGF therapy
Patients who present with CNV due to other causes than AMD, including pathological myopia, ocular histoplasmosis syndrome, angiod streaks, multifocal choroiditis, choroidal rupture
Patients with any retinal vasculopathies, including diabetic retinopathy, retinal vein occlusions, etc., in the study eye
Patients with previous subfoveal or juxtafoveal laser treatment
Patients with concomitant diseases in the study eye such as uveitis, retinal pigment epithelium rips, central serous corioretinopathy, acute ocular or peri-ocular infection
Patients with advanced glaucoma or intraocular pressure in the study eye > 22 mmHg in spite of adequate treatment or medication
Premenopausal women not using adequate contraception

Abbreviations: AMD, age-related macular degeneration; CNV, choroidal neovascularization; PDT, photodynamic therapy; VEGF, vascular endothelial growth factor; BCVA, best-corrected visual acuity.

Included previous treatments for wet AMD, such as laser, photodynamic therapy, or intravitreal anti-VEGF therapy, before arrival at our center.

We included in this analysis the first 67 patients treated with ranibizumab and the first 91 patients treated with bevacizumab.

At the first visit, best-corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts, stereoscopic fundus evaluation, fluorescein angiography (FA), and optical coherence tomography (OCT) with Stratus OCT, version 4.0.2 (Carl Zeiss Meditec, Dublin, CA, USA) were performed. OCT imaging consisted of 6 diagonal fast, low-density 6-mm scans and high density 6-mm scans with vertical and horizontal lines through the lesion. Foveal thickness was determined manually using callipers in the high-density vertical and horizontal lines.

CNV lesions were classified angiographically into predominantly classic, minimally classic, occult with no classic, or retinal angiomatous proliferations. All angiographic lesion subtypes, even those with areas of fibrosis, geographic atrophy, hemorrhage, or retinal pigment epithelium detachments greater than 50% of the size of the lesion were included in the study. Fibrotic scars without active CNV were not included in the study. ETDRS score was not an exclusion criterion. All patients with BCVA between 20/1000 and 20/20 were treated. In patients with very low ETDRS scores, intravitreal therapy was offered if further loss of visual function was recognized as detrimental to their quality of life. These patients included patients with subfoveal hemorrhages. Patients with visual acuity greater than 20/40 were treated when OCT and FA showed active CNV.

The existence of CNV was determined based on FA and OCT by two researchers (AMC and EMB).

Intravitreal via pars plana injection was performed if active CNV was identified on FA or if any intraretinal or subretinal fluid was present on OCT scans. Patients with a medical history of myocardial infarction or previous stroke were typically not treated, but the final decision was made with the patient based on a clinical risk/benefit evaluation for each case. Injection was performed in an operating room setting after a 3-day cycle of topical prophylactic ofloxacin. Cutaneous and conjunctival disinfection with iodopovidone was performed 5 min and immediately before the procedure. Ofloxacin was used topically during the 4 days following the procedure. Follow-up visits occurred in the normal clinical settings of our center, typically 28 ± 7 days after treatment. All patients were re-evaluated using ETDRS scores, fundoscopic examination, and OCT. The following re-treatment criteria were used: new macular hemorrhage or presence of subretinal or intra-retinal fluid on OCT or leakage on FA. No patient received combination therapy with photodynamic therapy, intravitreal triamcinolone, or any other anti-VEGF therapy. Re-injection was performed 5–7 days after the medical visit, depending on operating room availability.

Visual results were compared at baseline and at each re-evaluation.

The primary outcomes measured included variation in mean BCVA and in mean OCT foveal thickness between baseline and at 1, 2, 3, 4, 5, 6, 9, and 12 months.

Patients that suspended intravitreal treatment for non-ophthalmic reasons before completing the 12-month period were not included in efficacy analysis.

Moderate visual loss was considered when an ETDRS loss equal or superior to 15 letters occurred. Significant visual gain was considered when there was an ETDRS improvement of at least 15 letters. Mean BCVA ETDRS score variations were compared in both groups after each visit.

Statistical analysis was made using SPSS 16.0 (SPSS Inc, Chicago, IL, USA). Two-tailed t-tests were used to compare mean changes in BCVA and central retinal thicknesses on OCT. Chi-squared tests were used to compare non continuous variables. A P value of <0.05 was considered statistically significant. Values in the text are represented as the mean (standard deviation [SD]).
Results
Sixty-seven eyes of 67 patients were included in the ranibizumab cohort and 91 eyes of 91 patients were included in the bevacizumab-treated group. Visual acuity was similar between the groups at baseline. Both groups were similarly distributed in age and gender: 77.1 years and 41.8% males in the ranibizumab group and 76.5 years and 40.7% males in the bevacizumab group; \( P = 0.62 \) and \( P = 0.997 \), respectively (Table 2). Angiographic lesion subtypes were also similar (Table 2).

Mean BCVA at baseline was 20/160 (41.5 ETDRS score) in the ranibizumab group and 20/160 (40.6 letters) in the bevacizumab group (\( P = 0.72 \)).

Sixty patients treated with ranibizumab (90%) and 85 patients treated with bevacizumab (93%) completed 12 months of follow-up. Thirteen patients (6 in the bevacizumab group and 7 in the ranibizumab group) were lost during follow-up. Two patients from the bevacizumab group sustained a stroke and were not able to complete the 12 months of follow-up. There was no statistically significant difference in the number of patients lost to follow-up. All patients were included in statistical analysis until they were lost during follow-up.

In both groups, a significant increase was observed in visual acuity after 12 months of treatment. In the ranibizumab group (\( n = 60 \)), vision improved to 20/125 (48.8 letters), with a mean gain of +6.65 letters (\( P < 0.001 \)). In the 85 patients treated with bevacizumab, vision improved to 20/125 (47.6 letters), with a mean gain of +5.59 (\( P < 0.001 \)). However, there was no statistically significant difference in the number of patients lost to follow-up. All patients were included in statistical analysis until they were lost during follow-up.

In both groups, a significant increase was observed in visual acuity after 12 months of treatment. In the ranibizumab group (\( n = 60 \)), vision improved to 20/125 (48.8 letters), with a mean gain of +6.65 letters (\( P < 0.001 \)). In the 85 patients treated with bevacizumab, vision improved to 20/125 (47.6 letters), with a mean gain of +5.59 (\( P < 0.001 \)). However, there was no statistically significant difference between the two groups (\( P = 0.64 \)). Patients that did not complete 12 months of follow-up in both groups also experienced an overall gain of visual acuity at the date of the last visit: +3.5 letters in the ranibizumab group (initial mean BCVA 20.5 letters; mean follow-up of 108 days) and +6.4 letters in the ranibizumab group (initial mean BCVA 35.6 letters; mean follow-up time of 131 days).

Details regarding progression of variation of mean BCVA can be observed in Figure 1.

In the ranibizumab group, vision increased by 4.7 letters (\( n = 67 \), 100%; \( P < 0.001 \)) after the first treatment. In the bevacizumab group, the first injection yielded a visual improvement of 4.0 letters (\( n = 91 \), 100%; \( P = 0.001 \)).

Analysis of overall patient results at the end of the 12 months showed that 6.9% of patients had a moderate visual loss, including three ranibizumab-treated eyes (5.0%) and seven bevacizumab-treated eyes (8.2%). Visual gain occurred in 70.0% (\( n = 42 \)) of eyes treated with ranibizumab and 65.9% (\( n = 56 \)) of eyes treated with bevacizumab (\( P = 0.60 \)). Significant visual gain, defined as an increase of at least 15 ETDRS letters, occurred in 24.8% of eyes (15 eyes treated with ranibizumab, 25.0% and 21 eyes treated with bevacizumab, 24.7%). These differences between the groups were not statistically significant (\( P = 0.45 \) and \( P = 0.97 \), respectively).

Mean initial foveal thickness on OCT between the groups was statistically similar (318.3 \( \mu \)m in the ranibizumab group and 287.6 \( \mu \)m in the bevacizumab group; \( P = 0.19 \) (Table 2). There was a noticeable decrease in foveal thickness 1 month after the first treatment (ranibizumab: \(-103.9 \mu m\), \( P < 0.001 \) vs baseline; bevacizumab: \(-79.5 \mu m\), \( P < 0.001 \) vs baseline) that was not statistically different between treatment groups (\( P = 0.287 \)). This improvement was sustained throughout follow-up (Figure 2); at 12 months, mean foveal thickness was reduced by 115.15 \( \mu \)m (\( P < 0.001 \) vs baseline) in the ranibizumab group (\( n = 84 \)), and by

### Table 2 Baseline characteristics of the patients

<table>
<thead>
<tr>
<th>Ranibizumab (( n = 67 ))</th>
<th>Bevacizumab (( n = 91 ))</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age – mean (±SD)</td>
<td>77.1 (±7.1)</td>
<td>76.5 (±8.0)</td>
</tr>
<tr>
<td>Males – n (%)</td>
<td>28 (41.8%)</td>
<td>37 (40.7%)</td>
</tr>
<tr>
<td>Initial BCVA mean (±SD)</td>
<td>41.5 (±22.8)</td>
<td>40.6 (±20.5)</td>
</tr>
<tr>
<td>Initial foveal thickness mean (±SD)</td>
<td>318.3 (±136.9)</td>
<td>287.0 (±147.9)</td>
</tr>
<tr>
<td>Angiographic lesion subtype</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Predominantly classic</td>
<td>17</td>
<td>12</td>
</tr>
<tr>
<td>Minimally classic</td>
<td>18</td>
<td>31</td>
</tr>
<tr>
<td>Occult with no classic</td>
<td>24</td>
<td>39</td>
</tr>
<tr>
<td>RAP</td>
<td>8</td>
<td>9</td>
</tr>
</tbody>
</table>

Notes: <sup>a</sup>Pearson chi-square; <sup>b</sup>independent sample t-test.

Abbreviations: BCVA, best corrected visual acuity in ETDRS scores; SD, standard deviation; RAP, retinal angiomatous proliferation.

**Figure 1** Twelve-month variation of best corrected visual acuity in patients treated for wet age-related macular degeneration either with bevacizumab or ranibizumab. **Abbreviation**: ETDRS, Early Treatment Diabetic Retinopathy Study.
85.26 µm (P < 0.001 vs baseline) in the bevacizumab group (n = 64). This difference between groups was not significant (P = 0.19). Mean final foveal thickness was 206.58 µm for patients treated with ranibizumab and 196.69 µm for those that received bevacizumab (P = 0.534). Variations in foveal thickness compared to baseline for each group are presented in Figures 2 and 3 and Table 3.

The mean number of treatments performed per eye during the 12 months of follow-up was 5.97 (±2.1) for the ranibizumab group (n = 60) and 5.92 (±2.4) for the bevacizumab group (n = 85). This difference was not statistically different (P = 0.90).

The number of initial injections required to obtain a dry macula was variable. Three patients in the ranibizumab group and six patients in the bevacizumab group did not meet retreatment criteria one month after the first injection. During the following 11 months, only one patient (from the bevacizumab group) did not require further treatment. In 25.0% and 25.9% of the eyes in the ranibizumab and bevacizumab groups, respectively, a dry macula status was achieved without three initial consecutive injections (Table 4). No patients in either groups required monthly treatments during follow-up.

One patient in the bevacizumab group experienced vitreous hemorrhage and two patients in the ranibizumab group developed retinal pigment epithelium rips. There were no other significant ocular (endophthalmitis, retinal detachment, or cataract) side effects during the study.

In the bevacizumab group, one patient experienced a myocardial infarction while under treatment (9 months after the third initial monthly injection and did not require retreatment). One patient developed unstable angina pectoris but decided to continue treatment; she had no further complications during follow-up. Another patient was lost during follow-up following a stroke sustained 7 days after a bevacizumab injection (day 133 of follow-up; after three treatments). One lethal stroke was reported in the bevacizumab group after 8 months of follow-up and four initial monthly treatments. No systemic side effects were reported in the ranibizumab group.

**Discussion**

In this non-randomized, single-center, retrospective analysis, bevacizumab and ranibizumab achieved similar effects for the
control of wet AMD using a 1+PRN regimen of treatment. The mean gain in BCVA at 12 months was approximately six ETDRS letters in both groups with a mean number of nearly six injections.

Until recently, ranibizumab was the only drug that had been shown to improve mean BCVA in patients with wet AMD in large, double-blinded, multicentric randomized clinical trials.10,12,16–18 Bevacizumab showed promising results in the CATT trial,13 ABC trial,36 and in published series8,11,28,29,37–39 and is significantly cheaper than ranibizumab, allowing treatments of a greater number of patients. However, its intravitreal efficacy and safety are primary concerns for many ophthalmologists. Larger, randomized, prospective clinical trials comparing the two anti-VEGF molecules are in progress in different countries, but the results are not yet available.

In most reports describing the efficacy and safety of bevacizumab and ranibizumab, the drugs were investigated separately. The only direct comparison between the two molecules was performed in the CATT, which included four cohorts for comparing bevacizumab and ranibizumab in monthly or as-needed regimens of treatment. The results showed that ranibizumab given as-needed was equivalent to ranibizumab given monthly, with a mean difference of 1.7 letters. Bevacizumab given as-needed was equivalent to bevacizumab monthly over 36 weeks, but at 52 weeks the difference of 2.1 letters yielded an inconclusive comparison.13

Although our study was conducted in a clinical setting with no restrictions regarding BCVA at baseline or percentage of hemorrhage, atrophy or fibrosis in the CNV lesions, retreatment, and follow-up criteria were very similar to the CATT. In our series, initial vision was lower than in the CATT; however, our results are comparable to those of the as-needed cohorts of ranibizumab and bevacizumab in the CATT. At 12 months, the bevacizumab PRN group in the CATT improved by 5.9 letters, which is similar to our results (+5.59). The same is true for ranibizumab (6.8 letter gain in the CATT and 6.65 letter gain in our cohort). Mean visual gains were very similar despite differences in mean BCVA at baseline, which were lower in our patients (mean of 41 letters in our study vs mean of 60 letters in CATT). This shows that patients with low vision may also benefit from anti-VEGF therapy. The percentage of patients with moderate visual loss and significant visual gain were also very similar between the studies. The mean number of treatments performed was lower in our study compared to that in the CATT, but the visual results are nearly identical. Using the 1+PRN strategy of treatment, based on OCT and clinical data, we achieved a statistically significant and sustained visual gain over 12 months, with a mean of 5.97 injections in the ranibizumab group and 5.88 injections in the bevacizumab group. The number of injections was less than the number of injections in the CATT, which may be related to small differences in retreatment criteria. In the CATT, retreatment

Table 3 Outcome measures at month 12

<table>
<thead>
<tr>
<th></th>
<th>Ranibizumab (n = 60)</th>
<th>Bevacizumab (n = 85)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change from baseline BCVA score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean no of letters</td>
<td>6.65 (±13.9)</td>
<td>5.59 (±13.2)</td>
<td>0.64*</td>
</tr>
<tr>
<td>Increase of ≥15 letters (%)</td>
<td>15 (25.0)</td>
<td>21 (47.4)</td>
<td>0.97*</td>
</tr>
<tr>
<td>Increase of &gt;0 letters (%)</td>
<td>42 (70.0)</td>
<td>56 (65.9)</td>
<td>0.60*</td>
</tr>
<tr>
<td>Decrease of ≥15 letters (%)</td>
<td>3 (5.0)</td>
<td>7 (8.2)</td>
<td>0.45*</td>
</tr>
<tr>
<td>Foveal thickness (μm)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (±SD)</td>
<td>206.6 (±94.7)</td>
<td>196.7 (±93.3)</td>
<td>0.53*</td>
</tr>
<tr>
<td>Mean change from baseline (±SD)</td>
<td>−115.1 (±120.9)</td>
<td>−85.3 (±143.2)</td>
<td>0.19*</td>
</tr>
<tr>
<td>Mean no of treatments (±SD)</td>
<td>5.97 (±2.15)</td>
<td>5.92 (±2.36)</td>
<td>0.90*</td>
</tr>
</tbody>
</table>

Notes: *Pearson chi-square; †Independent samples t-test; ‡only 84 patients treated with bevacizumab had OCT data available at month 12.
Abbreviations: BCVA, best corrected visual acuity in Early Treatment Diabetic Retinopathy Study scores; RAP, retinal angiomatous proliferation.

Table 4 Number of initial consecutive injections to achieve a dry macula

<table>
<thead>
<tr>
<th></th>
<th>Ranibizumab n (%)</th>
<th>Bevacizumab n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 inj</td>
<td>3 (5.0)</td>
<td>6 (7.1)</td>
</tr>
<tr>
<td>2 inj</td>
<td>12 (20.0)</td>
<td>16 (18.8)</td>
</tr>
<tr>
<td>3 inj</td>
<td>10 (16.7)</td>
<td>26 (30.6)</td>
</tr>
<tr>
<td>4 inj</td>
<td>10 (16.7)</td>
<td>11 (12.9)</td>
</tr>
<tr>
<td>5 inj</td>
<td>13 (21.7)</td>
<td>8 (9.4)</td>
</tr>
<tr>
<td>6 inj</td>
<td>6 (10.0)</td>
<td>6 (7.1)</td>
</tr>
<tr>
<td>7 inj</td>
<td>0 (0)</td>
<td>4 (4.7)</td>
</tr>
<tr>
<td>8 inj</td>
<td>2 (3.3)</td>
<td>1 (1.2)</td>
</tr>
<tr>
<td>9 inj</td>
<td>2 (3.3)</td>
<td>5 (5.9)</td>
</tr>
<tr>
<td>10 inj</td>
<td>2 (3.3)</td>
<td>2 (2.4)</td>
</tr>
<tr>
<td>Mean†</td>
<td>4.20 inj</td>
<td>3.96 inj</td>
</tr>
</tbody>
</table>

Notes: *Difference between the mean number initial consecutive injections performed per eye in each group was not statistically significant (P = 0.53; independent samples t-test).
criteria included fluid on the OCT, new or persistent hemorrhage, decreased visual acuity as compared to the previous examination, or dye leakage or increased lesion size in FA. The lower threshold to fluid decided by trial investigators and wider retreatment criteria used in CATT likely led to a higher number of injections. In our series, 24.7% of eyes obtained significant visual gain, and less than 5% of patients had a maximum of 10 injections during the 12 months.

Apart from the CATT, only a few studies have compared bevacizumab to ranibizumab using the same treatment and retreatment protocols for both drugs. In the present study, bevacizumab showed similar results to ranibizumab as both drugs significantly improved mean BCVA and reduced foveal thickness. An expected, a statistically significant increase in BCVA and decrease in mean foveal thickness occurred in both groups after the first injection. Importantly, these changes, which were similar between the two cohorts, agreed with the results of previous studies and were maintained throughout the follow-up period.

Only one eye per patient was included in the study in order to eliminate bias that may have been introduced by using two eyes from the same patient. Including two eyes per patient may lead to a standard deviation with smaller amplitudes, resulting in biased statistically significant differences.

The strategy of treatment was 1+PRN. The data suggest that there is no benefit to using a three-injection loading dose rather than a 1+PRN regimen of treatment. This is similar to the results of the CATT. In our series, at least 25% of patients in each group did not require three initial consecutive injections as proposed by the European label of Lucentis®. Loading dose benefits are emphasized by many authors but have not been demonstrated in clinical trial settings and are label-recommended based only on statistical analysis, which may lead to overtreatment.

The increase in vision observed in the ranibizumab group was less than those observed in the ANCHOR, MARINA, and PrONTO trials, but higher than those observed in the PIER and SAILOR trials for the same time point. Our results using a 1+PRN regimen are comparable to those of SUSTAIN trial. Our retreatment criteria are more extensive than those used in the SUSTAIN trial; additionally, without an initial loading dose, the 12-month results are very similar. In both groups, a significant decrease in central foveal thickness was observed over the 12-month study period. Although the two groups differed in mean central foveal thickness at baseline, this difference was not statistically significant. However, the relationship between initial foveal thickness and response to treatment is not completely understood. It is presently not clear whether greater baseline foveal thickness leads to a greater improvement in visual acuity with any anti-VEGF treatment. However, mean central foveal thickness values were very similar immediately after the first injection and remained relatively stable during the 6 months of follow-up.

Non-statistically significant differences in efficacy observed in our study are in agreement with data from the CATT; both drugs are equally effective for treating wet AMD. This highlights very important economic issues. The disparity of prices between the two drugs is as important as the clinical findings, particularly regarding the connection between visual results and patient quality of life. However, systemic safety must be fully evaluated to understand the role of bevacizumab in the treatment of wet AMD.

There are several limitations to our study. This study was a retrospective, uncontrolled, non-randomized, and single-center study, which is insufficiently powered to identify differences in drug-related adverse events. The low number of patients and short follow-up time limit our ability to draw conclusions regarding safety. A small number of patients were treated and lost to follow-up for unknown reasons. Thus, we cannot speculate regarding the apparent higher rate of adverse events in the bevacizumab group.

Results from CATT, a large, multicentric, randomized prospective clinical trial, revealed no differences in treating wet AMD with either ranibizumab or bevacizumab using a 1+PRN strategy. Importantly, these results were found in a clinical setting. Thus, patients can be treated in regular clinical practice with either drug using this regime. However, large multicentric data are needed to make conclusions regarding systemic safety, which is an important factor in determining treatment.

Acknowledgments
We thank the technicians Hugo Monteiro, Paulo Rocha, and Fátima Matos for their dedication and work.

Disclosure
Ángela M Carneiro has participated in advisory boards for Novartis Pharma and Bayer.

Financial Support: grants from: “Sociedade Portuguesa de Oftalmologia” and “Hospital de São João”.

References
Clinical Ophthalmology downloaded from https://www.dovepress.com/ by 54.70.40.11 on 03-Feb-2019


22. Carneiro et al.

